Christopher Nutting: h-index, Total Citations, and Citation Map
Christopher Nutting's h-index is 82 (275 i10-index, 28,928+ total citations across 601+ publications) according to Google Scholar as of July 2026. Christopher Nutting is affiliated with Royal Marsden Hospital.
Christopher Nutting is a researcher affiliated with Royal Marsden Hospital, specializing in cancer. Their work has been cited 28,928 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Christopher Nutting's Citation Metrics
Bibliometric impact based on 601 indexed publications.
- H-Index
- 82
- i10-Index
- 275
- Total Citations
- 28,928
- Citing Countries
- 5
As of July 2026.
Christopher Nutting has an h-index of 82 and 28,928 total citations across 601 publications, with research cited by institutions in 5 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Christopher Nutting's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
20112,167
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Christopher Nutting's research
Christopher Nutting is a researcher in cancer at Royal Marsden Hospital. Their work has been cited 28,928 times across 601 publications (h-index 82), according to Google Scholar.
Their most-cited work, “Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial” (2011), has accumulated 2,167 citations. Other influential works include “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial” (2014) with 2,004 citations and “Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial” (2019) with 1,245 citations.
Citations of Christopher Nutting's research come primarily from China, United Kingdom and United States, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
